These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 29553863

  • 1. Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo.
    Jacobino SR, Nederend M, Reijneveld JF, Augustijn D, Jansen JHM, Meeldijk J, Reiding KR, Wuhrer M, Coenjaerts FEJ, Hack CE, Bont LJ, Leusen JHW.
    MAbs; 2018 Apr; 10(3):453-462. PubMed ID: 29553863
    [Abstract] [Full Text] [Related]

  • 2. Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater In Vivo Protection than the Murine Precursor of Palivizumab.
    Zhao M, Zheng ZZ, Chen M, Modjarrad K, Zhang W, Zhan LT, Cao JL, Sun YP, McLellan JS, Graham BS, Xia NS.
    J Virol; 2017 Aug 01; 91(15):. PubMed ID: 28539438
    [Abstract] [Full Text] [Related]

  • 3. Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion.
    Huang K, Incognito L, Cheng X, Ulbrandt ND, Wu H.
    J Virol; 2010 Aug 01; 84(16):8132-40. PubMed ID: 20519399
    [Abstract] [Full Text] [Related]

  • 4. Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab.
    Zhu Q, McAuliffe JM, Patel NK, Palmer-Hill FJ, Yang CF, Liang B, Su L, Zhu W, Wachter L, Wilson S, MacGill RS, Krishnan S, McCarthy MP, Losonsky GA, Suzich JA.
    J Infect Dis; 2011 Mar 01; 203(5):674-82. PubMed ID: 21208913
    [Abstract] [Full Text] [Related]

  • 5. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.
    Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK, White WI, Young JF, Kiener PA.
    J Mol Biol; 2007 May 04; 368(3):652-65. PubMed ID: 17362988
    [Abstract] [Full Text] [Related]

  • 6. Palivizumab epitope-displaying virus-like particles protect rodents from RSV challenge.
    Schickli JH, Whitacre DC, Tang RS, Kaur J, Lawlor H, Peters CJ, Jones JE, Peterson DL, McCarthy MP, Van Nest G, Milich DR.
    J Clin Invest; 2015 Apr 04; 125(4):1637-47. PubMed ID: 25751145
    [Abstract] [Full Text] [Related]

  • 7. Survival of Recombinant Monoclonal Antibodies (IgG, IgA and sIgA) Versus Naturally-Occurring Antibodies (IgG and sIgA/IgA) in an Ex Vivo Infant Digestion Model.
    Lueangsakulthai J, Sah BNP, Scottoline BP, Dallas DC.
    Nutrients; 2020 Feb 27; 12(3):. PubMed ID: 32120792
    [Abstract] [Full Text] [Related]

  • 8. Binding and Neutralizing Capacity of Respiratory Syncytial Virus (RSV)-Specific Recombinant IgG Against RSV in Human Milk, Gastric and Intestinal Fluids from Infants.
    Demers-Mathieu V, Lueangsakulthai J, Qu Y, Scottoline BP, Dallas DC.
    Nutrients; 2020 Jun 27; 12(7):. PubMed ID: 32605037
    [Abstract] [Full Text] [Related]

  • 9. A humanized monoclonal antibody against respiratory syncytial virus (palivizumab) inhibits RSV-induced neurogenic-mediated inflammation in rat airways.
    Piedimonte G, King KA, Holmgren NL, Bertrand PJ, Rodriguez MM, Hirsch RL.
    Pediatr Res; 2000 Mar 27; 47(3):351-6. PubMed ID: 10709734
    [Abstract] [Full Text] [Related]

  • 10. A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season.
    Fernández P, Trenholme A, Abarca K, Griffin MP, Hultquist M, Harris B, Losonsky GA, Motavizumab Study Group.
    BMC Pediatr; 2010 Jun 03; 10():38. PubMed ID: 20525274
    [Abstract] [Full Text] [Related]

  • 11. Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection.
    Detalle L, Stohr T, Palomo C, Piedra PA, Gilbert BE, Mas V, Millar A, Power UF, Stortelers C, Allosery K, Melero JA, Depla E.
    Antimicrob Agents Chemother; 2016 Jan 03; 60(1):6-13. PubMed ID: 26438495
    [Abstract] [Full Text] [Related]

  • 12. Broadly Reactive Anti-Respiratory Syncytial Virus G Antibodies from Exposed Individuals Effectively Inhibit Infection of Primary Airway Epithelial Cells.
    Cortjens B, Yasuda E, Yu X, Wagner K, Claassen YB, Bakker AQ, van Woensel JBM, Beaumont T.
    J Virol; 2017 May 15; 91(10):. PubMed ID: 28275185
    [Abstract] [Full Text] [Related]

  • 13. Motavizumab, a second-generation humanized mAb for the prevention of respiratory syncytial virus infection in high-risk populations.
    Weisman LE.
    Curr Opin Mol Ther; 2009 Apr 15; 11(2):208-18. PubMed ID: 19330726
    [Abstract] [Full Text] [Related]

  • 14. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
    Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B.
    Cochrane Database Syst Rev; 2013 Apr 30; (4):CD006602. PubMed ID: 23633336
    [Abstract] [Full Text] [Related]

  • 15. RSV neutralization by palivizumab, but not by monoclonal antibodies targeting other epitopes, is augmented by Fc gamma receptors.
    van Mechelen L, Luytjes W, de Haan CA, Wicht O.
    Antiviral Res; 2016 Aug 30; 132():1-5. PubMed ID: 27185625
    [Abstract] [Full Text] [Related]

  • 16. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
    Gilbert BE, Patel N, Lu H, Liu Y, Guebre-Xabier M, Piedra PA, Glenn G, Ellingsworth L, Smith G.
    Vaccine; 2018 Dec 18; 36(52):8069-8078. PubMed ID: 30389195
    [Abstract] [Full Text] [Related]

  • 17. A review of palivizumab and emerging therapies for respiratory syncytial virus.
    Shadman KA, Wald ER.
    Expert Opin Biol Ther; 2011 Nov 18; 11(11):1455-67. PubMed ID: 21831008
    [Abstract] [Full Text] [Related]

  • 18. Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab.
    Wu H, Pfarr DS, Losonsky GA, Kiener PA.
    Curr Top Microbiol Immunol; 2008 Nov 18; 317():103-23. PubMed ID: 17990791
    [Abstract] [Full Text] [Related]

  • 19. Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy.
    Hiatt A, Bohorova N, Bohorov O, Goodman C, Kim D, Pauly MH, Velasco J, Whaley KJ, Piedra PA, Gilbert BE, Zeitlin L.
    Proc Natl Acad Sci U S A; 2014 Apr 22; 111(16):5992-7. PubMed ID: 24711420
    [Abstract] [Full Text] [Related]

  • 20. Impaired Antibody-mediated Protection and Defective IgA B-Cell Memory in Experimental Infection of Adults with Respiratory Syncytial Virus.
    Habibi MS, Jozwik A, Makris S, Dunning J, Paras A, DeVincenzo JP, de Haan CA, Wrammert J, Openshaw PJ, Chiu C, Mechanisms of Severe Acute Influenza Consortium Investigators.
    Am J Respir Crit Care Med; 2015 May 01; 191(9):1040-9. PubMed ID: 25730467
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.